- First deliveries to Italy
- 100'000 face masks for Switzerland
- Efforts accelerated to develop new diagnostic testing and discover a treatment to prevent COVID-19 disease
AstraZeneca is donating nine million face masks, of which 100,000 are sent to Switzerland, to support healthcare workers around the world as they respond to the COVID-19 global pandemic. AstraZeneca has partnered with the World Economic Forum’s COVID Action Platform, created with the support of the World Health Organisation, to identify countries in greatest need. Italy already received the first shipments with other countries to follow.
100'000 face masks for Switzerland
Andrea Mugan, Country President of AstraZeneca Switzerland says: "Our thoughts are with the people suffering from the coronavirus and with the brave healthcare workers who are caring for them. Our company is partnering with international health authorities and others around the world to share our scientific knowledge and expertise in the fight against COVID-19. We donate nine million face masks worldwide, of which 100,000 have now been delivered to the Federal Office for Civil Protection FOCP, from where they are made available to the Swiss health care system".
“The Federal Office for Civil Protection expresses its sincere thanks for this generous gesture and greatly appreciates the associated contribution to overcoming the Corona crisis.”
The nine million masks were manufactured in China, where the large-scale and accelerated effort has been aided by AstraZeneca’s leading position and strong relationships with the country’s healthcare system and manufacturing sector.
Further efforts to mitigate the global impact of COVID-19
In addition to these donations, AstraZeneca is accelerating the development of its diagnostic testing capabilities to scale-up screening and is also working in partnership with governments on existing screening programmes to supplement testing.
AstraZeneca’s Research and Development (R&D) teams have also been working expeditiously to identify monoclonal antibodies to progress towards clinical trial evaluation as a treatment to prevent COVID-19. More than 50 virology, immunology, respiratory, and protein engineering experts across research, clinical, regulatory, and manufacturing are placing the highest priority on developing a treatment to minimise the global impact of COVID-19.
Since the start of the COVID-19 outbreak, AstraZeneca has already made several financial contributions, medicines and personal protective equipment donations to health organisations in China and several other countries around the world.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca in Switzerland
120 employees are responsible for coordinating business activities in Switzerland. Our location in Baar is furthermore the Headquarters of the Europe & Canada Commercial Regional team and the Europe & International Oncology teams, for which 40 additional employees work in Switzerland. Our most important therapeutic areas are Oncology; Cardiovascular and Diabetes; Respiratory, Inflammation and Autoimmunity. To achieve our climate targets ahead of schedule, we are working tirelessly to further reduce CO2 emissions and waste. Following our “Ambition Zero Carbon” strategy, we are doubling our energy productivity, using renewable energies to generate electricity and heat, and switch our entire fleet of company vehicles to electric vehicles. In 2020, AstraZeneca Switzerland was rated by employees as an excellent place to work for the third time in a row and was awarded the external label "Great place to work".
More information: astrazeneca.ch
Media Department AstraZeneca Switzerland
Tel. +41 (0) 41 725 75 75; firstname.lastname@example.org
Dr. Angelika März, Corporate Affairs Lead